Leader in #RNAiTherapeutics, having pioneered this innovative approach to silencing the genes that cause disease. Community guidelines: bit.ly/2FcRhJy.
Cambridge, MA
- Tweets 4,043
- Following 619
- Followers 17,396
- Likes 1,345
To our patients and their caregivers, we want to assure you that we are here to support you during these difficult times caused by #COVID19. People living in the U.S. can contact Alnylam Assist for personalized support in accessing our medicines, if prescribed by their doctor.
18
223
1,079
We know that due to #COVID19, patients & caregivers face unfamiliar and challenging circumstances. Alnylam Assist Case Managers are available to help those living in the U.S. prescribed our medicines with a full range of services including assistance with changes in site of care.
11
229
904
In a new LinkedIn #HardCases article, Dr. Bruce Wang of @ucsfhealth writes about the challenges faced by people living with acute hepatic #porphyria (AHP) in receiving an accurate diagnosis and his experiences as an AHP specialist. bit.ly/30GX13W
9
92
312
ICYMI, last week we announced that we have initiated ILLUMINATE-C, a global Phase 3 study of lumasiran, our investigational #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1), in patients with advanced renal disease, including patients on dialysis.
5
54
290
LinkedIn #HardCases recently published a new article by Dr. Bruce Wang of @UCSFhospitals in which he writes about the challenges in receiving an accurate diagnosis faced by people living w/ acute hepatic #porphyria (AHP) & his experiences working w/ patients as an AHP specialist.
6
74
256
Colin’s account of his “living nightmare” is all too familiar to people living with the debilitating pain and chronic symptoms of #porphyria #RareDisease bit.ly/2zzgB4v
13
92
241
We are pleased to announce that Alnylam Assist, our patient services program, can now provide patients in the U.S. prescribed GIVLAARI (givosiran) and their families with comprehensive support and guidance.
8
61
248
We’re committed to making the therapies we develop available to those who may benefit from them. Alnylam Assist provides patients in the U.S. with a range of services from assistance with insurance coverage to financial support and guidance.
3
39
242
Symptoms of #hATTR #amyloidosis can vary widely and resemble other conditions. If you’ve reached your tipping point where symptoms can no longer be overlooked, take the next steps - learn more about this #RareDisease and talk to your healthcare provider.
9
32
211
Despite three visits to the ER and undergoing countless tests, Amalia still had no answers to explain her recurring painful attacks. Learn how she found escape through her art as she navigated the challenging journey to receiving her diagnosis of acute hepatic #porphyria (AHP).
9
34
205
To all of the patients, family members, caregivers, advocates and healthcare professionals whose support and trust made this exciting news – the approval of ONPATTRO (patisiran) AND the 1st #RNAi therapeutic – possible, we say THANK YOU! #raredisease
6
40
191
We are thrilled to share the news that we have received @US_FDA approval for GIVLAARI (givosiran), the second #RNAi therapeutic from Alnylam approved by the FDA in less than 2 years. #raredisease #biotech
3
65
216
We're so proud to be named to the @BostonGlobe's #TopPlacestoWork 2018 list - our 4th yr in a row! Huge thanks to our >1000 passionate, patient-focused, "change the world" employees, who have said "#ChallengeAccepted" & are working to bring #RNAi therapeutics to patients in need.
6
49
172
Following her first acute hepatic #porphyria (AHP) attack, Amalia spent months of her teenage years searching for a diagnosis to explain her debilitating, unbearable symptoms. Watch Amalia explain this difficult time in her life through her artwork at our online art gallery.
7
20
161
Amalia was diagnosed with acute intermittent porphyria (AIP) after experiencing frequent, severe AHP attacks and other seemingly unrelated symptoms. Now, she’s using her artwork to share her experience navigating life with this RareDisease.
2
21
127
Getting the correct diagnosis of #porphyria allowed Colin and his doctor to better manage his symptoms and renew his quality of life bit.ly/2zzgB4v
4
41
141
Today’s approval of ONPATTRO (patisiran) by the @US_FDA is historic. It marks the arrival of a first-of-its-kind treatment – a medicine based on RNA interference (#RNAi), and also the first treatment option for patients in the U.S. living with a devastating #raredisease
6
49
140
With today’s approval of ONPATTRO (patisiran) in the U.S., we’re pleased to announce Alnylam Assist, our patient services program in the U.S., which provides patients and their families with comprehensive support and guidance.
3
23
128
People who may have hATTR amyloidosis can take advantage of Alnylam Act’s no-cost, third-party genetic testing & counseling through their doctor. Alnylam Act helps accelerate or confirm an #hATTR #amyloidosis diagnosis so people can make informed decisions about their health.
3
22
112
Excited to enter her freshman year of college, Amalia soon began experiencing unexplainable, excruciating symptoms. View Amalia’s artwork in Alnylam’s online gallery to learn more about her acute intermittent #porphyria (AIP) diagnosis and experience with this #RareDisease.
19
109
We couldn't resist offering Bernie a front row seat to the best show in #biotech town - the moment when #RNAitherapeutics (using Alnylam-synthesized #siRNA) work their magic by degrading target #mRNA thereby "silencing" the expression of specific genes that cause disease. #RNAi
7
19
122
#AlnylamScienceSpotlight: Our research leaders share how scientists harnessed #RNAi to create a new class of medicines in a @NatureBiotech perspective piece. RNAi technology is now poised to help millions of patients.
22
122
19,263
We are pleased to share topline results from our APOLLO-B phase 3 study of patisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy. #RNAitherapeutics #siRNA
1
34
119
Alnylam Assist offers comprehensive support and guidance to patients in the U.S. who are prescribed ONPATTRO (patisiran). Find out more about the wide range of services available at AlnylamAssist.com
5
20
107
We’re proud to be partnering w/ the Oxalosis & Hyperoxaluria Foundation (@OHFtweet) to develop PH1 of a Kind – a resource for the PH1 community. It’s an animated video series for kids (and caregivers, friends, and communities) about living w/ primary #hyperoxaluria type 1 (PH1).
1
20
99
Congratulations to @Novartis on @US_FDA approval of Leqvio (inclisiran). This is the 4th #RNAi therapeutic (#siRNA treatment) approved by the FDA, and the 4th such approval in this new class of medicines developed on Alnylam's #RNAitherapeutics platform.
1
16
117
We’re thrilled to share the news that we have received @US_FDA approval for OXLUMO (lumasiran), our third #RNAi therapeutic to receive regulatory approval in less than three years. #raredisease #biotech
1
34
119
We're proud to announce with our partners @Vir_biotech that we've identified what we believe to be a highly potent and broadly cross-reactive #RNAi therapeutic development candidate (DC) targeting SARS-CoV-2 for the treatment of #COVID19.
2
36
116
Today we announced that we’ve entered into a $2 billion strategic financing collaboration with @Blackstone to further accelerate the advancement of #RNAi therapeutics as an innovative new class of medicines. $ALNY
3
23
100
HCPs: Broaden your understanding of acute hepatic #porphyria (AHP) and what it takes to identify, diagnose and manage this #raredisease. Videos and resources are available in the @GoHealio AHP Education Lab. #gastroenterology #neurology #hematology #hepatology #internalmedicine
4
33
99
“#Porphyria can be an isolating disease even w/ caring physicians & loved ones by a patient’s side. It’s nearly impossible to comprehend the pain of AHP & the ways it impacts every aspect of a person’s life,” says Dr. Manisha Balwani of @MountSinaiNYC @SinaiGenetics #ILC2019
3
20
75
We are pleased to share positive topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. Read the press release: bit.ly/3VwvRtY #RNAiTherapeutics #siRNA
2
26
81
35,197
We believe that a diverse & inclusive workforce is critical to our ability to develop & deliver innovative new medicines to patients in need. We also know that diversity is part of what makes a career at Alnylam so great! Will you join us? Learn more: bit.ly/2jOnA2v
3
9
75
We are pleased to share positive topline results from our ILLUMINATE-A Phase 3 study of lumasiran, an investigational #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1). #raredisease #biotech
2
28
86
Congratulations to our SVP of Innovation #Chemistry and Alnylam Distinguished Scientist Muthiah (Mano) Manoharan, PhD, who has been awarded the Chemical Research Society of India (CRSI) 2022 Medal by @ChemResSocIndia. We are so #AlnylamProud! #RNAi #RNAitherapeutics #siRNA
1
9
78
We're very excited to be a @BostonGlobe Top Place to Work for the 3rd yr in a row. Thanks to our amazing employees! nitter.app/cards/18ce…
6
14
65
We’re thrilled to share the news that we have received @US_FDA approval for AMVUTTRA (vutrisiran), the fifth #RNAi therapeutic developed by Alnyam to receive regulatory approval in less than four years. #raredisease #biotech #RNAitherapeutics #siRNA
22
75
Alnylam was founded on this day 16 years ago by a small group of people who dreamed of translating the breakthrough discovery of #RNAi into a potential new class of medicines to improve the lives of patients worldwide. #biotechbirthdays 🎂🎉#16YearsofAlnylam #biotech #raredisease
3
16
67
Today, we announced that we have initiated ILLUMINATE-C, a global Phase 3 study of lumasiran, our investigational #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1), in patients with advanced renal disease, including patients on dialysis. #KidneyWeek
3
11
61
We’re pleased to announce that we’ve received a positive opinion from the @EMA_News Committee for Medicinal Products for Human Use (#CHMP) for our investigational #RNAi therapeutic for the treatment of #hATTR #amyloidosis. #raredisease
2
29
64
Join today’s webinar at 8PM ET to hear from Dr. Nance and Candace, who’s living with acute hepatic #porphyria (AHP), about the effects of AHP, tips for healthy living and how to enlist your care team. Dr. Nance, will also be sharing tips for patients with AHP related to #COVID19.
3
57
Heartfelt congratulations to our Muthiah "Mano" Manoharan, Ph.D., SVP of Drug Innovation Chemistry, on his @OTSociety Lifetime Achievement Award! Not only is Mano an internationally-renowned chemist and inventor, but he's also a beloved colleague, mentor and friend. #chemistry
5
19
64
We’ve announced the appointment of Nobel Laureate Carolyn Bertozzi, Ph.D. to our Board of Directors and existing board member Amy Schulman as the new Chair of the Board. Michael Bonney will step down as Executive Chair but continue to serve on the Board.
3
5
57
39,113
We’ll be holding our 2019 R&D Day this Friday, 11/22 from 8am – 1pm ET and will be webcasting the entire event LIVE. Click the link below to see the agenda, speaker bios and access the webcast.
1
20
52
Today, we are delighted to announce that the European Commission (@EMA_news) has approved our #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1), in both adults and children, which if left untreated can lead to life-threatening #kidney failure.
1
12
62
We're very pleased to announce the promotion of Dr. Akshay Vaishnaw to President. Akshay joined Alnylam in 2006 and has been a driving force behind the development of #RNAitherapeutics as an innovative new class of medicines, serving most recently as our head of R&D. #RNAi #siRNA
5
62
We believe that a diverse & inclusive workforce is critical to our ability to develop & deliver innovative new medicines to patients in need. We also know that diversity is part of what makes a career at Alnylam so great! Will you join us? Learn more: bit.ly/2jOnA2v
2
8
52
#ALNY & @Sanofi rpt Phase 3 results for RNAi tx: patisiran meets primary & all secondary endpts #hattr #amyloidosis nitter.app/cards/18ce…
3
40
60
We’re thrilled and honored that our first medicine, and the world’s first approved #RNAi therapeutic, was recognized by the @GalienFdn with a 2020 #PrixGalien USA award for “Best Biotechnology Product.” Congratulations to all of the winners and nominees. #AlnylamProud
1
15
61
Our #RNAi therapeutic for #hATTR #amyloidosis with stage 1 or 2 polyneuropathy has been approved today by the European Commission. It’s the first-ever #RNAi therapeutic to be approved in the EU and marks the next step in bringing a potentially life-changing treatment to patients.
2
14
57
One year ago, the approval of ONPATTRO (patisiran) marked the arrival of an entirely new class of medicines...and a dream pursued for over 15 years became reality. #RNAi #ChallengeAccepted #AlnylamProud
3
15
55
ICYMI: Our #RNAi therapeutic for #hATTR #amyloidosis with stage 1 or 2 polyneuropathy has been approved by the European Commission. It’s the first-ever #RNAi therapeutic to be approved in the EU & marks the next step in bringing a potentially life-changing treatment to patients.
9
55
HCPs: Join us Tuesday, 5/11 for a webinar with Dr. Michael Moritz, Prof. of Pediatrics at the University of Pittsburgh to learn about how metabolic stone diseases like primary #hyperoxaluria type 1 (PH1), may be the cause of your patients' #kidneystones. #raredisease #pediatrics
1
4
47
We’re growing quickly and looking for talented people who are ready to say “challenge accepted.” We have >130 open positions across the globe in >10 departments. Click below or visit us at booth 2825 to see if there’s a position perfect for you. #BIO2018 bit.ly/2jOnA2v
2
12
54
In a new @NatureBiotech article,@JMaraganore - our former founding CEO (02-21), reflects on our 20 yr journey from startup w/ an unproven therapeutic modality, through the challenges & opportunities common in #biotech, into a mature, multi-product, global #biopharma #Alnyalm20th
2
12
57
Our President, @BarryGreene & #Nobel Laureate Craig Mello, PhD (@craigedit) of @UMassMedical discussed the work to bring #RNAi from scientific discovery to FDA review as a potential new class of medicines at @Xconomy’s “What’s Hot in Boston #Biotech” earlier today.
1
12
50
With our partner @Regeneron, we are pleased to share interim Phase 1 clinical data on ALN-APP, an investigational #RNAi therapeutic in development for the treatment of #alzheimersdisease and cerebral amyloid angiopathy. #RNAitherapeutics #siRNA
3
18
50
12,184
Alnylam CEO @JMaraganore spoke w/ @Forbes @matthewherper about how we will seek to work w/ payers, physicians & patients to make sure that patients who will benefit from our medicines can access them, when approved. #ForbesHealth bit.ly/2AJ1ARU
8
10
46
We stand with the Black community and all people of color. Systemic racism and exclusion of any kind cannot be tolerated. We are our greatest as a society when we treat everyone with dignity, respect and in the same way we would wish to be treated by others.
8
50
We are very pleased to announce that we have formed a significant new collaboration with @Regeneron focused on advancing #RNAi therapeutics for eye and CNS diseases.
16
50
Check out the latest issue of @NatureBiotech! It features Alnylam science on the cover AND in a new article: “Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates.” #RNAi #RNAiTherapeutics #siRNA #AlnylamProud
The October issue is live nature.com/nbt/volumes/40/is…
On our cover, 2′-𝘖-hexadecyl (C16)-conjugated siRNA in complex with RISC and mRNA. C16-conjugated siRNA achieves efficient, durable targeted gene silencing in the central nervous system, eye and lung go.nature.com/3aEbgQH
10
50
We’re SO excited! We’ve been named the #1 science employer for 2019 by @ScienceMagazine and @ScienceCareers. Congratulations to all of the innovative, science-driven companies on this year’s list! #biotech #biopharma
2
15
52
We are pleased to share that we have completed the rolling submission of a new drug application (NDA) to the @US_FDA for givosiran, an investigational #RNAi therapeutic for the treatment of acute hepatic #porphyria (AHP).
13
48
We're pleased to announce today that we've initiated a rolling submission of a New Drug Application (NDA) to the @US_FDA for lumasiran, an investigational #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1). #raredisease
10
48
We’ve shared topline results from our APOLLO-B phase 3 study of patisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. We’ll present full results at #ISA_2022 in September. #RNAitherapeutics #siRNA
7
49
We are pleased to announce new interim results from our ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational #RNAi therapeutic targeting liver-expressed angiotensionogen (AGT) for the treatment of #hypertension. #RNAitherapeutics #siRNA #Hypertension2021
16
46
We're pleased to announce that we've submitted a clinical trial application (CTA) for ALN-APP, an investigational #RNAi therapeutic in development for the treatment of #AlzheimerDisease and cerebral amyloid angiopathy. #RNAitherapeutics #siRNA
8
47
We're thrilled to be nominated for the 2019 U.S. #PrixGalien Award for Best Biotechnology Product for ONPATTRO (patisiran), the world's first approved #RNAi therapeutic. Congrats to all of the nominees! @GalienFdn #biotech
1
10
45
Our newly announced collaboration w/ @Regeneron combines both companies’ scientific and technological expertise and will build on Alnylam’s recent pre-clinical data showing potent and highly durable delivery of #RNAi therapies to achieve target #genesilencing in the eye and CNS.
15
42
We are pleased to share we have completed submissions of a New Drug Application to the @US_FDA and Marketing Authorization Application to the European Medicines Agency for lumasiran, our investigational #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1).
7
42
We are further expanding our existing collaboration with @Vir_Biotech to advance #RNAi therapeutics for the treatment of coronavirus infection, including #COVID19, to evaluate three host factors required for SARS-CoV-2 infection, including ACE2 and TMPRSS2.
2
15
38
Today, we are delighted to announce that the European Commission (@EMA_news) approved our #RNAi therapeutic for the treatment of #hATTR #amyloidosis with stage 1 or 2 polyneuropathy, an inherited and fatal disease affecting tens of thousands worldwide.
2
11
46
We're thrilled & honored to be recognized today by @FastCompany as one of the World's 50 Most Innovative Companies for our work translating the breakthrough discovery of #RNAi into an innovative new class of medicines! #FCMostInnovative #biotech
13
46
Today’s @US_FDA approval marks the arrival of a new treatment option for adults diagnosed with the polyneuropathy of #hATTR #amyloidosis, a #raredisease that can have devastating consequences, for which there are few treatment options. #RNAi #RNAitherapeutics #siRNA
13
44
Today, our leadership team rang the @Nasdaq opening-bell to mark 20 yrs of Alnylam leadership in #RNAi, innovation and perseverance, and what's next in the #RNAiRevolution. Alnylam was founded on 6/14/02 and went public as $ALNY in May '04. #RNAitherapeutics #Alnylam20th #siRNA
ALT A group of men and women stand behind the Nasdaq opening bell podium.
ALT A group of men and women stand outside in New York City's time square in front of the Nasdaq marquee.
ALT A group of men and women stand behind the Nasdaq opening bell podium, cheer and clap as confetti falls around them.
ALT Alnylam's CEO, Dr. Yvonne Greenstreet, stands behind the Nasdaq bell ringing podium.
2
7
44
Today, we are pleased to report positive topline results from an interim analysis of ENVISION, our Phase 3 study of givosiran, an investigational #RNAi therapeutic for the treatment of acute hepatic #porphyrias (AHPs). #RareDisease
16
43
We are pleased to share topline results from our KARDIA-1 Phase 2 study of zilebesiran, an investigational #RNAi therapeutic in development for the treatment of #hypertension in patients with high cardiovascular risk. #RNAiTherapeutics #siRNA
1
4
41
13,663
Launching a biotech is hard, especially for young founders, who face many barriers to success. That’s why we’re partnering with @NucleateHQ to support the next gen of #biotech entrepreneurs with mentoring, funding and more. #entrepreneurship #biotechnology #bioventures #startups
12
44
We’re thrilled to share that our pivotal Phase 3 APOLLO data for patisiran, an investigational #RNAi therapeutic for the treatment of #hATTR #amyloidosis were published in @NEJM.
1
14
37
Congratulations to our @BarryGreene on once again being named to the #PharmaVOICE100 list and on receiving his Red Jacket Award! @PharmaVOICE recognized Barry for his passion, integrity and being a patient champion. Read more at the link below.
2
7
42
We are very pleased to announce the promotion of Dr. Yvonne Greenstreet, our current COO, to the role of President and COO, as part @BarryGreene's planned transition. Yvonne is a respected and accomplished #biopharma executive who has served as our COO for the past four years.
1
3
38
This morning, our partner @MDCONews shared topline results from the ORION-11 Phase 3 study of inclisiran, our investigational #RNAi therapeutic for the treatment of hypercholesterolemia. #PCKS9 #siRNA bwnews.pr/2Nxcakn
2
14
40
Physician-scientist, drug-developer, trailblazer, veteran #biopharma leader and now, our incoming CEO. Get to know Dr. Yvonne Greenstreet (@ygreenst) in a new @BostonGlobe profile piece. #leadership #RNAi #RNAitherapeutics #siRNA bit.ly/3o3Ne5T
4
39
We are pleased to share that the @US_FDA has accepted our supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of #ATTR #amyloidosis. #RNAitherapeutics #siRNA
8
37
10,371
Today, we are delighted to announce that the European Commission (@EMA_news) has approved our #RNAi therapeutic for the treatment of acute hepatic #porphyria, a devastating #raredisease, which until now had limited treatment options.
10
38
Alnylam and @Novartis have announced a collaboration to discover and develop an #siRNA -based targeted therapy (utilizing our #RNAi therapeutics platform) as a potential alternative to transplantation for patients with end-stage liver disease (ESLD). #RNAitherapeutics
7
40
We are pleased to share that the @US_FDA has granted Fast Track designation to vutrisiran, our investigational #RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) #amyloidosis in adults.
11
38
We are pleased to announce that the @US_FDA has accepted the New Drug Application (NDA) for givosiran, our investigational #RNAi therapeutic for the treatment of acute hepatic #porphyria (AHP) and granted it Priority Review.
12
43
We are pleased to share @US_FDA has accepted the New Drug Application (NDA) for patisiran, our investigational #RNAi therapeutic for the treatment of #hATTR #amyloidosis, and granted it Priority Review Status. nitter.app/cards/18ce…
9
41
Today, we announce important news for patisiran, our investigational #RNAi therapeutic for #hATTR #amyloidosis. nitter.app/cards/18ce…
2
18
40
We’re headed to Paris for the EU ATTR #amyloidosis Meeting to present new data & meet with the #hATTR amyloidosis community.
10
40
We are pleased to announce that the @US_FDA has granted Orphan Drug Designation to ALN-TTRsc02, a subcutaneously delivered investigational #RNAi therapeutic for the treatment of transthyretin-mediated #amyloidosis. #raredisease
1
14
38
Today, with @SanofiGenzyme, we announced that the FDA has lifted the hold on clinical studies with fitusiran, our investigational #RNAi therapeutic for #hemophilia. nitter.app/cards/18ce…
2
13
38
We are pleased to announce our 2nd collaboration with @Regeneron. This one is focused on the discovery of new RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH).
1
22
39
Congrats to our CEO @JMaraganore on being voted the 2019 @statnews best #biotech CEO. His passion for our science and unwavering commitment to helping people living with disease motivates and inspires us every day...and has since 2002! #RNAi #leadership bit.ly/2Sbx6zP
6
38
Congrats to our CEO @jmaraganore for being recognized, w/ @spark_tx's @jeffmarrazzo, as #Bloomberg50 health innovators. John & Jeff both personify the innovative spirit and dedication to improving the lives of patients living w/ #raredisease that drive the companies they lead.
11
37